**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Annelore Vandendriessche; Department of Diagnostic Sciences, Ghent University; Ghent, East Flanders, Belgium

**Main Body of the Abstract**
Be.Amycon addresses the urgent need for improved amyloidosis diagnosis and management in Belgium through a comprehensive, multi-center approach. The goal is to enhance patient outcomes by establishing a collaborative network of dedicated researchers and clinicians, tackling difficulties in diagnosis and typing of amyloid, leading to faster diagnosis, earlier treatment intervention and new therapeutic options. Our initiative encompasses a range of strategies aimed at transforming the current state of amyloidosis management in Belgium. One focus is the implementation of mass spectrometry for amyloid typing. By optimizing the diagnostic process we aim to deliver more timely and precise diagnoses, offering a leap forward in patient care. In addition to technical advancements, an educational program for healthcare providers will be initiated, in conjunction with a close collaboration with the patient advocacy in order to centralize and optimize patient care. The initiative’s holistic vision covers the entire spectrum of amyloidosis research and care, from fostering awareness and expertise, to establishing a decentralized biobank for amyloidosis samples, to deep proteomics analysis of protein deposits. At this international amyloidosis conference, we aim to share insights into the challenges faced in Belgium while presenting the broader goals of Be.Amycon. We not only want to address immediate changes in amyloidosis care, but also meet high standards for comprehensive, collaborative efforts in the field. We aim to share our vision and progress, hoping to inspire similar approaches worldwide.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
**Annelore Vandendriessche; Department of Diagnostic Sciences, Ghent University; Ghent, East Flanders, Belgium**

**Main Body of the Abstract**
**Be.Amycon addresses the urgent need for improved amyloidosis diagnosis and management in Belgium through a comprehensive, multi-center approach. The goal is to enhance patient outcomes by establishing a collaborative network of dedicated researchers and clinicians, tackling difficulties in diagnosis and typing of amyloid, leading to faster diagnosis, earlier treatment intervention and new therapeutic options. Our initiative encompasses a range of strategies aimed at transforming the current state of amyloidosis management in Belgium. One focus is the implementation of mass spectrometry for amyloid typing. By optimizing the diagnostic process we aim to deliver more timely and precise diagnoses, offering a leap forward in patient care. In addition to technical advancements, an educational program for healthcare providers will be initiated, in conjunction with a close collaboration with the patient advocacy in order to centralize and optimize patient care. The initiative’s holistic vision covers the entire spectrum of amyloidosis research and care, from fostering awareness and expertise, to establishing a decentralized biobank for amyloidosis samples, to deep proteomics analysis of protein deposits. At this international amyloidosis conference, we aim to share insights into the challenges faced in Belgium while presenting the broader goals of Be.Amycon. We not only want to address immediate changes in amyloidosis care, but also meet high standards for comprehensive, collaborative efforts in the field. We aim to share our vision and progress, hoping to inspire similar approaches worldwide.**



Advancing Amyloidosis Management in Belgium: The Belgian Amyloidosis Consortium (Be.Amycon) PA95 (#157)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.